Fig. 7
From: High resolution optical mapping of cardiac electrophysiology in pre-clinical models
Flecainide-induced conduction slowing in mouse left atria. (a) Example activation maps at baseline and following 1 µM flecainide treatment of mouse left atria. (b) Group data of conduction velocity before and following 1 µM flecainide treatment of mouse left atria at a range of pacing cycle lengths (PCLs). c) Grouped data of conduction velocity at baseline and 20 minutes later from mouse left atria at a range of PCLs. n = 5. Two-way ANOVA, *P < 0.05, ***P < 0.001, ****P < 0.00001 between baseline and flecainide/time control respectively. Overall interaction of CV with PCL and flecainide/time is shown to the bottom right of the figures *P < 0.05, ***P < 0.001.
